C34 Categoría · se requiere mayor especificidad Malignant neoplasm of bronchus and lung
ICD-10-CM C34 identifies “Malignant neoplasm of bronchus and lung” as a category requiring further specificity in the FY2027 U.S. classification, effective October 1, 2026 through September 30, 2027.
Capítulo 2: Neoplasms
Instrucciones del código
Excludes 12
Instrucciones de niveles superiores
Capítulos 2 · Neoplasms (C00-D49)
Note8
- Functional activity
- All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
- Morphology [Histology]
- Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
- Primary malignant neoplasms overlapping site boundaries
- A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
- Malignant neoplasm of ectopic tissue
- Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
C30-C39 · Malignant neoplasms of respiratory and intrathoracic organs (C30-C39)
Includes1
malignant neoplasm of middle ear
Excludes 11
mesothelioma (C45.-)
Códigos más específicos
C34.0Malignant neoplasm of main bronchusCategoría · se requiere mayor especificidadC34.1Malignant neoplasm of upper lobe, bronchus or lungCategoría · se requiere mayor especificidadC34.2Malignant neoplasm of middle lobe, bronchus or lungCódigo facturable y específicoC34.3Malignant neoplasm of lower lobe, bronchus or lungCategoría · se requiere mayor especificidadC34.8Malignant neoplasm of overlapping sites of bronchus and lungCategoría · se requiere mayor especificidadC34.9Malignant neoplasm of unspecified part of bronchus or lungCategoría · se requiere mayor especificidadReferencias del índice oficial
Referencias desde otros códigos (4)
Code first · malignant neoplasm of bronchus and lung (C34.-)
Inclusion terms · Conditions classifiable to C33-C34
Inclusion terms · Conditions classifiable to C34
Excludes 2 · malignant neoplasm of bronchus and lung (C34.-)
Historial
Historial del código
Último cambio registrado · FY2017
Vigente desde
- Cambios en instrucciones
Malignant neoplasm of bronchus and lung
Categoría — seleccione un código más específico
CDC/NCHS · FY2017Todas las ediciones (19)
| Todas las ediciones | Vigente desde | Historial del código |
|---|---|---|
| FY2016 | 2015-10-01 | Primera aparición |
| FY2017 | 2016-10-01 | Cambios en instrucciones |
| FY2018 | 2017-10-01 | Sin cambios tabulares |
| FY2019 | 2018-10-01 | Sin cambios tabulares |
| FY2020 | 2019-10-01 | Sin cambios tabulares |
| FY2020 · April | 2020-04-01 | Sin cambios tabulares |
| FY2021 | 2020-10-01 | Sin cambios tabulares |
| FY2021 · 01-01 | 2021-01-01 | Sin cambios tabulares |
| FY2022 | 2021-10-01 | Sin cambios tabulares |
| FY2022 · 04-01 | 2022-04-01 | Sin cambios tabulares |
| FY2023 | 2022-10-01 | Sin cambios tabulares |
| FY2023 · 04-01 | 2023-04-01 | Sin cambios tabulares |
| FY2024 | 2023-10-01 | Sin cambios tabulares |
| FY2024 · 04-01 | 2024-04-01 | Sin cambios tabulares |
| FY2025 | 2024-10-01 | Sin cambios tabulares |
| FY2025 · 04-01 | 2025-04-01 | Sin cambios tabulares |
| FY2026 | 2025-10-01 | Sin cambios tabulares |
| FY2026 · April | 2026-04-01 | Sin cambios tabulares |
| FY2027 | 2026-10-01 | Sin cambios tabulares |
Explora los códigos más específicos de esta categoría. La comprobación del catálogo no establece la pertinencia clínica ni garantiza el reembolso.